1,899 results on '"Kumada, Hiromitsu"'
Search Results
102. Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment
103. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma
104. Histological impact at 5 years after the start of sodium-glucose cotransporter 2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus
105. High Virus Titer, Slow Virus Decrease, Genotype II, and Sequence Variability of E2/NS1 HVR Predict Poor Response to Interferon Therapy in Chronic Hepatitis C
106. The safety of chemotherapy for colorectal cancer patients with hepatitis C virus infection
107. Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine
108. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies
109. In Hepatocellular Carcinomas, any Proportion of Poorly Differentiated Components is Associated with Poor Prognosis After Hepatectomy
110. Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up
111. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B
112. HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials
113. Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b
114. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
115. Clinicopathological indices to predict hepatocellular carcinoma molecular classification
116. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients
117. Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals.
118. The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis.
119. ITPA Polymorphism Affects Ribavirin-Induced Anemia and Outcomes of Therapy—A Genome-Wide Study of Japanese HCV Virus Patients
120. Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage
121. Renal safety and biochemical changes for two years of tenofovir alafenamide after switching from long‐term other nucleotide analogues treatment in patients with chronic hepatitis B
122. Comparison between Lumipulse Presto HBsAg-HQ and iTACT-HBsAgin Chronic Hepatitis B with Seroclearance of HBsAg by Architect HBsAg QT
123. Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir
124. Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
125. Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis
126. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis
127. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration
128. Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan
129. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study
130. Randomized Trial of Interferon- and Ribavirin-Free Ombitasvir/Paritaprevir/Ritonavir in Treatment-Experienced Hepatitis C Virus–Infected Patients
131. HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy
132. Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b
133. Potential impact of joint association of alanine aminotransferase and gamma-glutamyltransferase on insulin resistance in Japan: The Toranomon Hospital Health Management Center Study 19 (TOPICS 19)
134. Implication of an extremely high preoperative alpha-fetoprotein value (>4,000 ng/mL) for the long-term outcomes of hepatectomy for resectable hepatocellular carcinoma
135. A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C
136. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study
137. Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers
138. Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis
139. Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study
140. Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study
141. Two cases receiving retreatment with 12 weeks of glecaprevir and pibrentasvir for HCV genotype 2 infection who failed prior glecaprevir and pibrentasvir therapy
142. Additional file 2 of Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study
143. Additional file 1 of Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study
144. A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma
145. Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection
146. Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan
147. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus
148. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients
149. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C
150. Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.